JUNS Jupiter Neurosciences, Inc.
Listings ·
Nasdaq says the stock closed below $1.00 for 30 consecutive business days and that its market value of listed securities stayed below $35 million. The company has until August 25, 2026 on both, and its auditor has raised going-concern doubt.
Jupiter said it needs more time to complete the presentation and review of its financial statements. It expects to file within five calendar days of the deadline and says it anticipates no significant change in results.
Nasdaq confirmed on July 9, 2025 that Jupiter's stock held an average closing price of at least $1.00 over 13 days. The company's last annual report still carries a going concern warning.
Jupiter Neurosciences received a Nasdaq letter on March 21, 2025 saying its stock fails the $1.00 minimum bid price rule. The company has until September 17, 2025 to regain compliance.
Jupiter Neurosciences priced a firm commitment IPO of 2,750,000 shares at $4.00, or $11,000,000 gross. Its prospectus carries a going concern warning and an accumulated deficit of $23,903,481 at June 30, 2024.
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company in Jupiter, Florida. It is developing treatments for neuroinflammation and central nervous system (CNS) disorders and rare diseases using its JOTROL resveratrol platform, an enhanced oral formulation of resveratrol. Its primary target is Parkinson's disease, where it is conducting a Phase IIa clinical trial. The company says the IND for that trial received final FDA approval in November of 2025, and the trial is expected to start in the second quarter of 2026, with results anticipated 12 months later. It also aims to investigate Mild Cognitive Impairment and Alzheimer's disease after the Parkinson's study. The company has service agreements with firms in Hong Kong to accelerate product development in Southeast Asia, and an agreement with Dominant Treasure Health to expand business development in China, Malaysia and Singapore. It also sells Nugevia, a consumer line of nutritional products for longevity and wellness, sold direct-to-consumer through social media. Shipments began in the fourth quarter of 2025. The company reports two segments: premium nutritional supplements under the Nugevia brand, and pharmaceutical operations centered on drug candidates.
| Product or program | What it is | Stage |
|---|---|---|
| JOTROL | Enhanced oral formulation of resveratrol, the company's platform product | Phase IIa in Parkinson's disease, expected to start second quarter 2026 |
| Nugevia GLO | Consumer supplement supporting cellular function and skin vitality | available for sale |
| Nugevia MND | Consumer supplement supporting cognitive resilience | available for sale |
| Nugevia PWR | Consumer supplement supporting mitochondrial function | available for sale |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $21,796 | |
| Research and development | $2.1 million | $492,660 |
| Net income (loss) | -$8.6 million | -$2.4 million |
| Cash from operations | -$5.4 million | -$3.9 million |
Our latest story on this, dated Feb 27, 2026: "Jupiter Neurosciences gets two Nasdaq notices on minimum bid price and market value". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 2, 2024: "Jupiter Neurosciences prices $11 million IPO of 2,750,000 shares at $4.00". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 27, 2026: "Jupiter Neurosciences gets two Nasdaq notices on minimum bid price and market value". The story links the filing or release it is based on. Read the story.
Jupiter Neurosciences, Inc. trades under the ticker JUNS on NASDAQ.
Jupiter Neurosciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Jupiter Neurosciences, Inc. is 1679628. Its filings are on SEC EDGAR.
770,081 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Jupiter Neurosciences, Inc. under United States.
Our directory classifies Jupiter Neurosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Jupiter Neurosciences, Inc. is US48208B3024.
aibio.space lists Jupiter Neurosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company in Jupiter, Florida. It is developing treatments for neuroinflammation and central nervous system (CNS) disorders and rare diseases using its JOTROL resveratrol platform, an enhanced oral formulation of resveratrol.
JOTROL: Enhanced oral formulation of resveratrol, the company's platform product Stage: Phase IIa in Parkinson's disease, expected to start second quarter 2026.
Nugevia GLO: Consumer supplement supporting cellular function and skin vitality Stage: available for sale.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 424B5. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a financing. SEC Form 424B4. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio